Discounted Cash Flow Rating

Return on Equity Rating

Debt to Equity Rating

Price to Earnings Rating

Analyst Rating

()

No description provided.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/01/1970

Market Cap

N/A

Shares Outstanding

N/A

Weighted SO

N/A

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

Beta

N/A

Last Div

N/A

Range

N/A

Chg

N/A

Avg Vol

N/A

Mkt Cap

N/A

Exch

N/A

Country

N/A

Phone

N/A

DCF Diff

N/A

DCF

N/A

Div Yield

N/A

P/S

N/A

EV Multiple

N/A

P/FV

N/A

Div Yield %

N/A

P/E

N/A

PEG

N/A

Payout

N/A

Current Ratio

N/A

Quick Ratio

N/A

Cash Ratio

N/A

DSO

N/A

DIO

N/A

Op Cycle

N/A

DPO

N/A

CCC

N/A

Gross Margin

N/A

Op Margin

N/A

Pretax Margin

N/A

Net Margin

N/A

Eff Tax Rate

N/A

ROA

N/A

ROE

N/A

ROCE

N/A

NI/EBT

N/A

EBT/EBIT

N/A

EBIT/Rev

N/A

Debt Ratio

N/A

D/E

N/A

LT Debt/Cap

N/A

Total Debt/Cap

N/A

Int Coverage

N/A

CF/Debt

N/A

Equity Multi

N/A

Rec Turnover

N/A

Pay Turnover

N/A

Inv Turnover

N/A

FA Turnover

N/A

Asset Turnover

N/A

OCF/Share

N/A

FCF/Share

N/A

Cash/Share

N/A

OCF/Sales

N/A

FCF/OCF

N/A

CF Coverage

N/A

ST Coverage

N/A

CapEx Coverage

N/A

Div&CapEx Cov

N/A

P/BV

N/A

P/B

N/A

P/S

N/A

P/E

N/A

P/FCF

N/A

P/OCF

N/A

P/CF

N/A

PEG

N/A

P/S

N/A

EV Multiple

N/A

P/FV

N/A

DPS

N/A

Latest Headlines (EST)

GlobeNewswire Inc. Jun 07, 22:30 Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color GlobeNewswire Inc. May 30, 05:00 Communiqué de presse : L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO GlobeNewswire Inc. May 30, 05:00 Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials GlobeNewswire Inc. May 30, 05:00 Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies The Motley Fool Mar 25, 22:47 Why Pharma and Biotech Stocks Got Thrashed on Tuesday GlobeNewswire Inc. Mar 12, 01:32 Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem GlobeNewswire Inc. Mar 01, 20:13 REGN ?????????????????? ROSEN ???? 10 ?????? Regeneron Pharmaceuticals, Inc. ????? REGN ??????????????? 3 ? 10 ?????? GlobeNewswire Inc. Mar 01, 20:13 REGN FINAL DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – REGN GlobeNewswire Inc. Feb 27, 01:10 REGN DEADLINE ALERT: Regeneron Pharmaceuticals (REGN) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class Action GlobeNewswire Inc. Feb 23, 19:03 ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN GlobeNewswire Inc. Feb 21, 00:26 ROSEN, LEADING TRIAL ATTORNEYS, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN GlobeNewswire Inc. Feb 19, 00:53 REGN STOCK NEWS: Robbins LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025 GlobeNewswire Inc. Feb 18, 05:59 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP) GlobeNewswire Inc. Feb 12, 23:57 Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit– Hagens Berman GlobeNewswire Inc. Feb 12, 02:04 ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN GlobeNewswire Inc. Feb 09, 04:34 ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN GlobeNewswire Inc. Feb 08, 22:40 EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting GlobeNewswire Inc. Feb 08, 20:55 Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals GlobeNewswire Inc. Jan 29, 02:02 ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN GlobeNewswire Inc. Jan 19, 16:13 ROSEN, A RANKED AND LEADING FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

Revenue Product Segmentation